PureTech Health plc (PRTCY)

Market Cap	380.31M -6.1%
Revenue (ttm)	6.37M -0.4%
Net Income	2.11M -95.8%
EPS	0.08 -96.1%
Shares Out	n/a
PE Ratio	207.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101
Open	16.34
Previous Close	17.29
Day's Range	16.34 - 16.34
52-Week Range	13.93 - 19.92
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 22, 2026

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 90
• Stock Exchange: OTCMKTS
• Ticker Symbol: PRTCY

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error